Establishing Pompe Disease Newborn Screening: The Role of Industry

When clinical trials for enzyme replacement therapy for Pompe disease commenced, a need for newborn screening (NBS) for Pompe disease was recognized. Two methods for NBS for Pompe disease by measuring acid α-glucosidase in dried blood spots on filter paper were developed in an international collabor...

Full description

Bibliographic Details
Main Author: Joan M. Keutzer
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Neonatal Screening
Subjects:
Online Access:https://www.mdpi.com/2409-515X/6/3/55
_version_ 1797563304810381312
author Joan M. Keutzer
author_facet Joan M. Keutzer
author_sort Joan M. Keutzer
collection DOAJ
description When clinical trials for enzyme replacement therapy for Pompe disease commenced, a need for newborn screening (NBS) for Pompe disease was recognized. Two methods for NBS for Pompe disease by measuring acid α-glucosidase in dried blood spots on filter paper were developed in an international collaborative research effort led by Genzyme. Both methods were used successfully in NBS pilot programs to demonstrate the feasibility of NBS for Pompe disease. Since 2009, all babies born in Taiwan have been screened for Pompe disease. Pompe disease was added to the Recommended Uniform (Newborn) Screening Panel in the United States in 2015. NBS for Pompe disease is possible because of the unprecedented and selfless collaborations of countless international experts who shared their thoughts and data freely with the common goal of establishing NBS for Pompe disease expeditiously.
first_indexed 2024-03-10T18:40:47Z
format Article
id doaj.art-9bcc77274f1a41d096419d423b036297
institution Directory Open Access Journal
issn 2409-515X
language English
last_indexed 2024-03-10T18:40:47Z
publishDate 2020-07-01
publisher MDPI AG
record_format Article
series International Journal of Neonatal Screening
spelling doaj.art-9bcc77274f1a41d096419d423b0362972023-11-20T05:53:04ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2020-07-01635510.3390/ijns6030055Establishing Pompe Disease Newborn Screening: The Role of IndustryJoan M. Keutzer0Sanofi Genzyme, Cambridge, MA 02142, USAWhen clinical trials for enzyme replacement therapy for Pompe disease commenced, a need for newborn screening (NBS) for Pompe disease was recognized. Two methods for NBS for Pompe disease by measuring acid α-glucosidase in dried blood spots on filter paper were developed in an international collaborative research effort led by Genzyme. Both methods were used successfully in NBS pilot programs to demonstrate the feasibility of NBS for Pompe disease. Since 2009, all babies born in Taiwan have been screened for Pompe disease. Pompe disease was added to the Recommended Uniform (Newborn) Screening Panel in the United States in 2015. NBS for Pompe disease is possible because of the unprecedented and selfless collaborations of countless international experts who shared their thoughts and data freely with the common goal of establishing NBS for Pompe disease expeditiously.https://www.mdpi.com/2409-515X/6/3/55newborn screeningPompe diseaseacid α-glucosidase
spellingShingle Joan M. Keutzer
Establishing Pompe Disease Newborn Screening: The Role of Industry
International Journal of Neonatal Screening
newborn screening
Pompe disease
acid α-glucosidase
title Establishing Pompe Disease Newborn Screening: The Role of Industry
title_full Establishing Pompe Disease Newborn Screening: The Role of Industry
title_fullStr Establishing Pompe Disease Newborn Screening: The Role of Industry
title_full_unstemmed Establishing Pompe Disease Newborn Screening: The Role of Industry
title_short Establishing Pompe Disease Newborn Screening: The Role of Industry
title_sort establishing pompe disease newborn screening the role of industry
topic newborn screening
Pompe disease
acid α-glucosidase
url https://www.mdpi.com/2409-515X/6/3/55
work_keys_str_mv AT joanmkeutzer establishingpompediseasenewbornscreeningtheroleofindustry